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The ideal drug delivery system delivers drug at a 
rate dictated by the need of the body over the period 
of treatment and it channels the active entity solely 
to the site of action. At present no available drug 
delivery systems can achieve all these goals. The 
targeted drug delivery system achieves the site 
specific delivery but is unable to control the releas  
kinetics of drug in predictable manner. Since then 
numerous attempts have been made to device 
clinically effective drug delivery system(s). Number 
of carriers were utilized to carry drug at target 
organ/tissue which include immunoglobulins, serum 
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proteins, synthetic polymers, lipid vesicles 
(liposomes), microspheres, erythrocytes, reverse 
micelles, niosomes, pharmacosomes etc. amongst 
the various carries, few drug carriers reached drug 
delivery to the site of action. These carriers 
(liposome) are biologically inert in nature, devoid f 
any antigenic, pyrogenic or allergic reactions and 
their components can be utilized as the component 
of biological membrane. Drug incorporated in 
liposomes are not inactivated under physiological 
conditions and do not cause unfavorable side effects 
as well1. 
Structurally, liposomes are concentric bilayer 
vesicles in which an aqueous volume is entirely 
enclosed by a membranous lipid bilayer mainly 
composed of natural or synthetic phospholipids2. 
There are many approaches to production of 
liposomes and each method has inherent advantages 
and limitations. Since the shelf life of liposomal 
suspensions can be limited, it would be useful to 
have a method of producing liposomes quickly, at 
the point of use and without excessive manipulation. 
These needs are met by the “proliposome” method. 
Proliposome (PLs) are simply soluble particles 
covered with liposome precursors which, when 
dissolved in water, will produce liposomes. Payne 
et.al (1986a, 1986b) originally developed this 
method3. Being available in dry powder form, they 
are easy to distribute, transfer, measure and store 
making it a versatile system. Liposomes can either 
be formed in vivo under the influence of 
physiological fluids or can be formed in vitro prior 
to administration using a suitable hydrating fluid. 
The liposomes formed on reconstitution are similar 
to conventional liposomes and more uniform in 
size4. 
Advantages of proliposomes5 
• Targeting of anti-cancer drugs to tumor sites. 
• Targeting of drugs to non-RE tissues, which has 
not been possible with conventional liposomes. 
• Proliposomes can use for controlling release 
within the vasculature by manipulating the 
phospholipid composition of bi-layers. 
• For the diseases of vascular origin, proliposomes 
provide the best therapeutic effect over 
conventional drug. 
Comparisons between liposomes and 
proliposomes6 
Liposomes are unilamellar or multilamellar spheroid 
structures composed of lipid molecules, often 
phospholipids. They show controlled release and 
increased solubility but have a tendency to aggregate 
or fuse, susceptible to hydrolysis or oxidation. 
Proliposomes an alternative forms to conventional 
liposomal formulation composed of water soluble 
porous powder as a carrier, phospholipids and drugs 
dissolved in organic solvent. Lipid and drug are 
coated onto a soluble carrier to form free-flowing 
granular material show controlled release, better 
stability, ease of handling and increased solubility. 
Components used for the preparation of 
proliposomes 
Water soluble carriers7 
The carrier’s chosen should have high surface area 
and porosity so that the amount of carrier required 
can be easily adjusted to support the lipids. It also 
enables high surfactant to carrier mass ratio in the 
preparation of proliposomes. Further, being water 
soluble they allow rapid formation of liposomal 
dispersion on hydration and by controlling the size 
of porous powder, relatively narrow range of 
reconstituted liposomes can be obtained. Some of 
the carriers utilized include- maltodextrin, sorbitol, 
microcrystalline cellulose, magnesium aluminium 
silicates, Mannitol etc. 
Phospholipids8-9 
The bulk components of liposomal lipid membrane 
are phosphotindyl glycerides (phospholipids), 
amphipathic molecules that consist of a hydrophilic 
phosphate head group and hydrophilic fatty acid 
chains bridged together by a glycerol back bone. In 
early studies, egg phosphatidylcholine (egg PC, egg 
lecithin) was used and these phospholipids. 
Although exhibiting a single head group 
composition, contain various lipid species due to the 
presence mixed and varying acyl chain lengths. 
More recently highly purified lipids have been 
chemically synthesized consisting of saturated fatty 
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acid species with same numbers of carbons. The 
fatty acid chain can vary between 8-24 carbons (C8-
C24); among them thee mostly used in liposomal 
drug delivery are myristic (C14), palmitic (C16) and 
steric (C18). Aside from the fatty acid carbon length, 
the phosphate group can varied and include 
phosphatidylcholine (PC). 
Phosphotindlyethanolamine (PE), which are 
zwitterion (charge balanced with positive charge on 
head group and negative charge on phosphate 
group), the negatively charged phosphatidly, serine, 
glycerol inositol head group. Many of 
physicochemical properties of liposomes such as 
stability, permeability, phase behavior and 
membrane order depend on the fatty acid chain 
length and saturation. 
Steroids8-9 
Cholesterol is a generally used steroid in the 
formulation of liposomes to membrane and reduces 
the permeability of water- soluble molecules through 
the membrane and improves the stability of bilayer 
membrane in the presence of biological fluids such 
as blood/plasma. Liposomes without cholesterol ten 
to react with the blood proteins such as albumin, m-
transferrin and macroglobulin, which tend to 
destabilize the liposomes. Cholesterol appears to 
reduce these interactions with blood proteins. 
Solvents10 
They are used to for providing the softness for 
vesicle membrane. Examples of solvents are 
methanol and chloroform. 
Method of preparation of proliposomes 
Proliposome could be prepared by many methods 
such as: 
• Film- deposition on carrier method. 
• Fluidised-bed method. 
• Spray drying method. 
• Super critical antisolvent method. 
Film- deposition on carrier method1-11 
For preparing proliposome by this method special 
equipment as  Buchi rotary evaporator ‘R’ with 
water cooled condenser coil and a stainless steel 
covered thermocouple connected to a digital 
thermometer, is required. The end of the glass 
solvent inlet tube is modified to a fine point, so that 
the solvent is introduced into the flask as a fine 
spray. 
Procedure 
The solution of lipid and drug in volatile organic 
solvent is prepared and carrier powder is introduce 
into 100ml flask. The flask is then fitted into the 
evaporator and rotated slowly so that the powder 
tumbles gently off the walls to ensure good mixing 
and the solvent is evaporated. The flask is lowered 
into a water bath at 50-550C when a good vacuum as 
developed (around 100 KPa). An aliquot of 5ml of 
lipid solution is introduced into the flask via the 
solvent inlet tube. The solvent is absorbed 
completely by the powder and the temperature of the 
bed is monitored. As evaporation proceeds, the 
temperature will decrease. A second aliquot is 
introduced slowly when the temperature begin 
again. The temperature allowed rising to 300C, the 
vacuum is released and drying process is completed 
by connecting the flask containing the powder to 
lyophilize and leaving it evacuated overnight at 
room temperature. 
For use, introduce 10ml of distilled water into one 
vial and mix on a whirl mixer for 30sec. or in 
shaking water bath above the lipid phase transition 
temperature, to give a 5%w/v solution of sorbitol( 
isotonic with normal saline) and a lipid 
concentration of 10mg/ml. 
Care must be taken not to allow temperature rise too 
high if working with low melting temperature (e.g. 
egg PC) otherwise agglomeration of powder 
particles will result. 
Fluidised bed method12-13 
Principle  
It works on the principle of particle coating 
technology. 
Usage of carrier material  
The carrier material used here can vary from 
crystalline powder to non pareil beads. When using 
beads as carrier material, initial seal coating is 
applied to the beads to provide a smooth surface for 
further coating of phospholipids. This ensures 
formation of thin uniform coating of phospholipid 
around the core and formation of smaller sized 
liposomes upon hydration.  
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Procedure 
Solution of drug and phospholipid in organic solvent 
is sprayed onto the carrier material through a nozzle. 
At the same time, the organic solvent is removed by 
applying vacuum to the fluid bed. To remove the 
trace amount of residual solvent the finished lipid-
coated powder/beads can be dried under vacuum 
overnight.  
Advantages 
• It utilizes Film coating technology which is well 
established and process able. 
• Various cores and coating materials are available 
or easy to prepare.  
• It is a cost-effective method to prepare 
liposomes for drug delivery. 
Spray drying method14- 16 
This method is mainly used when particles of 
uniform size and shape are required and can be 
easily scaled up it is cost effective and suitable for 
large scale production of proliposomes. The unique 
feature of spray drying process lies in its ability to 
involve both particle formation and drying in a 
continuous single step, allowing better control of 
particle. Spray drying is not only limited to aqueos 
solutions, but can also be used for non-aqueous 
systems to prepare particles. 
The spray drying process involves four stages: 
1. Atomization of the product into a spray nozzle. 
2. Spray-air contact. 
3. Drying of the spray droplets, and  
4. Collection of the solid product. 
Procedure 
Initially liquid dispersions containing pure lipid or 
lipids and carrier in organic solvent are prepared an
pumped into the drying chamber. The dispersions 
are atomized into the drying chamber using a spray 
nozzle and are dried in a concurrent air flow which 
is then collected in a reservoir. 
Major concerns to spray drying are high working 
temperatures, shearing stresses and absorption 
phenomenon that may lead to thermal and 
mechanical degradation of the active molecules. 
This can be improved by optimising the operating 
parameters such as drying air temperature and liquid 
spraying rate. Stabilising adjuvants such as 
disaccharides, cyclic oligosaccharides and polyols 
can also be used to protect the integrity of the active 
molecules and enhance the efficiency of hydration 
by increasing the surface area of lipids. 
Super critical anti-solvent method17-18 
Supercritical anti solvent method utilizes 
Supercritical Carbon dioxide (SCCO2) in the 
preparation of PLs. SCCO2 is a fluid state of carbon 
dioxide where it is held at or above its critical 
temperature and pressure. Antisolvent technology is 
widely used in food industry and was developed to 
prepare PLs because of its lower residual solvents, 
simpler steps and mild operation temperatures. 
As shown in Figure No.1, the apparatus used in the 
preparation of PLs include three parts:  
• A sample delivery unit, 
• A precipitation unit and 
• A separation unit. 
The sample delivery unit consists of two pumps: one 
for CO2 and the other for solution. CO2 is supplied 
from the CO2 cylinder (1) which is cooled down by 
a refrigerator (2) and introduced via a high pressure 
pump (3) to the buffer tank (4), in which it is 
preheated. The drug solution is introduced via HPLC 
pump (11). The solvent used for dissolving the drug 
should be completely miscible with CO2. Opening 
the valves A and B allows the entry of solution and 
CO2 into the vessel through the nozzle (B). As seen 
in Fig 3.B, solution is sprayed through the inner 
tubule whereas CO2 is sprayed through the outer 
tubule of the nozzle. The precipitation unit consists 
of a vessel (9) heated by an air bath. The separation 
unit consists of a separator (13) and a wet gas meter 
(14). The organic solvent is separated from SCCO2 
in the separator because of lower pressure whereas 
volumetric flow rate of CO2 is measured by the wet 
gas meter. After the temperature and pressure of the 
separating vessel reaches the present value, valve A 
is opened to allow entry of CO2 followed by 
opening of valve B allowing the entry of drug 
solution. SCCO2 and solution are mixed and 
diffused into one another rapidly as they are sprayed 
through the coaxial nozzle. This causes the solutes 
dissolved in organic solvent to reach super 
saturation in a very short period of time because the 
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solubility of solutes in the organic solvent decreases 
greatly. As a result, the PLs are precipitated in the 
vessel. Once the solution is completely utilized, 
valves A and B are closed while valve C is opened 
in order to depressurize the vessel at the operating 
temperature. The samples are collected on the filter
(8) at the bottom of the vessel. The pressure, 
temperature and flow rate of the drug solution need 
to be optimized to obtain high drug loading in 
proliposomes. 
 
CHARACTERIZATION OF PROLIPOSOMES 
The proliposomes are evaluated by following are the 
parameters: 
Vesicle Size determination 
Vesicle Size determination is one of the most 
important parameter for vesicular system. This can 
be carried by hydrating the proliposomes powder 
and determining vesicle size using suitable Particle 
size analyzer or determined by using an optical 
microscope with a calibrated eyepiece micrometer7. 
Scanning Electron Microscopy (SEM)   
Surface morphology of proliposomes and plain 
water soluble carrier were examined by a scanning 
electron microscope. After gold coating of 
proliposome and plain water soluble carrier, their 
surface morphology was viewed. This involves 
comparing the image of the pure carrier material 
with that of the proliposomes. The SEM image of 
the carrier material confirms the deposition of 
phospholipid on the carrier and thus confirming the 
formation of proliposomes19. 
Transmission Electron Microscopy (TEM) 
TEM is mainly used to study the morphology of the 
liposomes from proliposome upon hydration and 
observing the shape and lamellarity of the liposome 
vesicles formed under the microscope7-19. 
Hydration Study 
Hydration study is to evaluate the ability of 
proliposomes to form liposomes on hydration. It is 
carried by placing a small amount of proliposomes 
powder on glass slide slowly adding water drop wise 
while observing it under the microscope to view the 
formation of vesicles7, 19.  
 
Zeta potential  
The zeta Potential is defined as the difference in 
potential between the surface of the tightly bound 
layer (shear plane) and the electro-neutral region of 
the solution. This can be used to study the surface 
charge of the particles20. 
Flow Property 
It ensures the despite the deposition of 
phospholipids on carriers, the flow ability of 
particles is not affected. This can be done by 
measuring the parameters such as Angle of Repose, 
Carr’s Index or Compressibility Index and 
Hausner’s Ratio7-19.  
Entrapment Efficiency 
Entrapment efficiency is carried by hydrating the 
proliposomes to form liposome dispersion followed 
by separation of unentrapped drug and determining 
the amount of drug entrapped. The unentrapped drug 
can be separated by cooling ultracentrifugation7.  
 Percent drug entrapment is calculated by using the 
following formula: 
Entrapped Drug X 100/Total Amount of Drug 
added 
Application  
Proliposomes can be exploited for the following 
routes of administration: 
Oral delivery  
Oral drug delivery continues to be the preferred 
route of administration, but liposomes have limited 
success in delivering drugs through oral route. This 
is due to the absence of a stable dosage form oral 
delivery and erratic and unpredictable absorption 
profiles shown by liposomes. Being available as free
flowing powder, PL represents the first example of 
delivering liposomes into solid dosage form such as 
tablets or capsules. Further, liposomes are formed on 
contact with biological fluids at the site of 
absorption ensuring the retention of liposome 
integrity. 
Zaleplon is a hypnotic drug indicated in insomnia 
and is a potential anticonvulsant. Due to its limited 
aqueous solubility and extensive first pass 
metabolism it shows poor bioavailability of 30%. 
PLs for oral delivery of Zaleplon and found 2-5 fold 
improvement in oral bioavailability in rats compared 
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to pure drug4. 
Arthritis 
Drug that are being in arthritis especially steroids, 
are destroyed by their peripheral effect. On local 
administration into the joints, drug diffuses easily 
from the site of injection and its action on the 
inflamed area is only transient. Segal et.al suggested 
that liposomes could be used in the treatment of 
local diseases. It is observed that steroids (e.g. 
cortisol palmitate) can be entrapped into large 
multilamellar liposomes composed of dipalmitoyl 
phosphatidyl choline and phosphatidic acid. These 
preparations, when ingested into rabbits with 
experimental arthritis, can decrease the temperature 
as well as the size of the joints to a greater extent 
than with a similar amount of free steroids1. 
Diabetes 
The feasibility of using liposomes as a potential 
delivery system of the oral delivery of insulin has 
been extensively studied. Alteration in blood 
glucose level in diabetic animals was obtained by 
the oral administration of liposome encapsulated 
insulin. Dobre et.al demonstrated a lowering of 
blood glucose level in normal rats following the oral 
administration of insulin entrapped in PC: CH 
liposomes1. 
Parenteral delivery 
PLs are well suited for parenteral application of 
liposomes. The main advantage    associated with 
PLs is that it allows sterilization without affecting 
the intrinsic characteristics11. Besides, they can be 
stored as sterilized in dry state and can be hydrate  
prior to administration to form multilamellar 
liposomal suspension21. 
Pulmonary Delivery 
Major advantage of liposomes as pulmonary drug 
delivery system is that they are prepared from 
phospholipids which are endogenous to lungs as 
component of lung surfactant. Drug encapsulation in 
liposomes provides modulated absorption, resulting 
in localized drug action in the respiratory tract and 
prolonged drug presence in circulation and reduced 
systemic adverse effects22, 23. 
Drug delivery to the pulmonary route is achieved by 
three types of devices namely 
 
Pressurised metered dose Inhalers (pMDI) 
As the name suggests it consists of solution or 
suspension of drugs in liquefied propellants. Use of 
Hydrofluroalkanes as non-ozone depleting 
propellants over CFCs has the limitation for 
liposome delivery as they are poor solvents for 
phospholipids. Proliposomes help overcome this 
limitation as they can be suspended in these 
propellants and serve as carrier for pulmonary 
delivery of liposomes through pMDI22. 
Dry Powder Inhalers (DPIs) 
These disperse the drug into the patient’s airstream 
as a fine powder during inhalation. Delivering 
liposomes through DPI have many advantages such 
as controlled delivery, increased potency, and 
reduced toxicity, uniform deposition of drugs 
locally, patient compliance, stability and high dose 
carrying capacity. Being available as dry powder 
form, PLs are the best alternative for delivering 
liposomes through DPIs. Chougule et.al developed 
spray dried liposome encapsulated Dapsone DPI for 
prolonged drug retention in lungs to prevent 
Pneumocystis carinii pneumonia. Prolonged drug 
release of up to 16 h was observed in vitro22, 24. 
Nebulizers 
Nebulization offers the simplest means, for 
delivering liposomes to the human respiratory tract 
but it is concerned with liposome leakage and drug 
stability. Use of dry powder formulations has been 
suggested to overcome these issues. Lyophilisation 
and jet milling may be used to obtain dry powder but 
tend to have deleterious effect on liposomes due to 
the stresses involved in these processes. Thus, PLs 
serve as a stable alternative for delivering liposomes 
through nebulization. Besides, the ready formation 
of an isotonic liposome formulation in situ from PLs 
seems to offer advantages over other formulation 
approaches22, 23. 
Mucosal delivery 
PLs form vesicular structures (liposomes) in vivo, 
triggered by the aqueous environment found on the 
mucosal surfaces. Phospholipids present in them 
have natural affinity for biological membranes. 
Besides they are generally nontoxic and non-irritant. 
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The presence of drug as molecular dispersion in the 
bilayers offers improved drug activity. Further, the 
difficulties associated with liposomal preparations 
such as stability and loading are circumvented 
because the PLs convert to vesicular structures in 
vivo, i.e., on the mucosa25. 
Vaginal delivery systems are frequently required to 
treat local fungal infections. The poor aqueous 
solubility of antifungal and steroid compounds in 
conventional formulations limits their presence as 
molecular dispersion and consequently affects the 
drug concentration at active sites. The associations 
of these lipophilic agents with the phospholipid 
molecules of proliposome make them excellent 
carriers to molecularly disperse the drug25. 
Nasal mucoadhesive delivery has been used to 
improve local and systemic delivery of therapeutic 
compounds26. Limitations associated with this route 
are mucociliary clearance which limits the residence 
time of drug in the nasal cavity and lack of sustained 
release of drugs with short half-life27,28. 
Proliposomal delivery helps to overcome these 
limitations. Liposomes formed on hydration 
decrease the mucociliary clearance of drug due to 
their surface viscosity and provide intimate and 
prolonged contact between the drug and mucus 
membrane29,30. 
Transdermal delivery 
Phospholipids, being the major component of 
liposomal system, can easily get integrated with the 
skin lipids and maintain the desired hydration 
conditions to improve drug permeation. When PLs 
are applied to mucosal membrane, they are expected 
to form liposomes on contact with mucosal fluids 
whereby the resulting liposomes act as sustained 
release dosage form for loaded drugs. Liposomes 
formed on hydration have the ability to modulate 
diffusion across the skin. They do so by fusing with 
the skin surface and establishing concentration 
gradient of the intercalated drug across the skin. 
Thus they enhance skin permeation. Also, the 
vesicle intercalation into the intracellular lipid layers 
of the skin results in fluidization and disorganization 
of the regular skin structure, obviating the barrier 
function of the stratum corneum21, 31. 
Ophthalmic delivery of drugs 
The potential of liposomes in topical ocular drug 
delivery was first focused by Smolin et al. Schaeffer 
and Krohn and Schaeffer et al. liposomes offer 
advantages over most ophthalmic preparation in 
being completely biodegradable and relatively non-
toxic. Smolin et al. reported the treatment of acute 
and chronic herpetic keratitis in albino rates, 
idoxuridine entrapped in liposomes was more 
effective than a comparable therapeutic regimen of 
unentraped drug. Schaeffer et al. reported that 
transcorneal flux of penicillin G, indoxol and 
Carbachol were approximately double when these 
drugs were presented to the corneal surface in 
liposomal form. In direct contrast to these findings, 
Starford et al., observed a reduction in the fraction 
of epinephrine and inulin absorbed into aqueous 
humor in liposomes1. 
Liposomes as carrier for vaccines 
Liposomes as immunological adjuvants 
Studies on cardiolipin (naturally occurring lipids) 
revealed the imported of bilayer structure in 
production of antisera and concluded that liposomes 
are in fact responsible for the antigenicity of the 
lipids. In addition, liposomes also have an adjuvant 
effect upon protein antigen. Liposomes can serve as 
an effective for inducing HI to wide range liposomal 
antigens. 
The size and structure of liposomes may be 
modulated as required which effect the 
immunogenic of liposomised antigens. Studies on 
HLVs and ULVs of comparable size promoting 
antibody response revealed that ULVs are more 
effective than HLVs to entrap BSA. 
Liposomes made from the lipids with temperature 
above the ambient temperature (370C) are known to 
behavior differently from liposomes made from 
lipids whose Tcs are below the ambient temperature 
with interacting with the cells. Liposomes composed 
of Dipalmitoyl phosphatidyl choline and Distearoyl 
phosphatidyl choline (Tc: 41.00C and 554.90C, 
respectively) have been reported to be more 
effective immunogens than those prepared from egg 
PC because of the greater bilayer stability at 
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physiological temperature and stronger immune-
potentiating property1. 
Liposomes as carrier of antigens 
In addition their adjuvant effect, liposomes have 
been recognized as efficient carrier to deliver 
biologically active material to specific cells. 
However, on administration of liposomes the major 
fraction is taken up by the liver and spleen unless 
steps are taken to retard their uptake.  
The following criteria help in successful homing of 
liposomised agent to target cells. 
• Rate of uptake of liposome by RES must be 
minimized by using small, neutral, unilamellar 
liposomes having higher Tc and cholesterol. 
• By coupling the surface of liposomes which 
would render liposomes less recognizable by 
RES. 
• Coupling appropriate molecules (ligands) on the 
liposome surface which can bind to their 
receptors on the surface of target cell1.    
Literature review on proliposomes drug delivery 
system 
Diwan et al., studied on proliposomal gel bearing a 
steroidal anti-inflammatory agent Prednisolone 
intended for topical application. They  prepared 
proliposomes by thin film hydration technique by 
using varying the lipid phase composition 
(lecithin/cholesterol) and reported that Prednisolone 
proliposomal gel showed sustain release with 
enhanced anti-inflammatory activity implicating its
potential in effective topical pharmacotherapy for 
the treatment of rheumatoid arthritis32. 
Mallesh Kurakula et al., studied on proliposomal 
gel bearing a non-steroidal anti-inflammatory agent, 
Piroxicam intended for topical application. 
Proliposome formulations were prepared by thin 
film hydration technique using varying the lipid 
phase composition (lecithin/ cholesterol). They 
reported that the Piroxicam proliposomal gel showed 
sustain release with enhanced anti-inflammatory 
activity implicating its potential in effective topical 
pharmacotherapy for the treatment of rheumatoid 
arthritis33. 
Arpana Patil-Gadhe et al., prepared Rifapentine-
loaded proliposomes for the treatment of 
tuberculosis by spray drying method and 
independent variables were optimized using factorial 
design approach. The study results demonstrated the 
application of quality by design principles and 
design of experiment approach to develop drug 
encapsulated proliposomes for inhalation by spray 
drying in single step34. 
Chuandi Sun et al., investigated the possibility of 
liquid proliposomes being carriers for oral delivery. 
They prepared Nimodipine liquid proliposomes-
based soft capsules and reported that proliposomes 
shows potential way to improve oral delivery of 
Nimodipine35. 
Rajesh Kumar et al., formulated proliposomes in 
the form of enteric-coated beads using Glyburide as 
a model drug. The beads were enteric coated with 
Eudragit L-100 by a fluidized bed coating process 
using triethyl citrate as plasticizer. The dissolution 
study of enteric-coated beads exhibited enhanced 
dissolution compared with pure drug and a marketed 
product36. 
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Figure No.1: Apparatus for preparing PLs by Supercritical Anti Solvent Method 
 
CONCLUSION  
Proliposomes exhibited superior shelf life as 
compared to liposomes and it offers non-invasive 
delivery of drug into or across the skin. Since better 
stability of liposomes in vitro is observed with 
proliposomes, the proliposomes would be proper 
choice of preparation method. Introduction of 
proliposomes has initiated a new area in vesicular 
research for topical drug delivery. Different reports 
show a promising future of proliposomes in making 
transdermal delivery of various agents. 
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